BASi Launches Innovative Glucose Monitoring Project With Pinnacle Technology

  BASi Launches Innovative Glucose Monitoring Project With Pinnacle Technology

      New Option for High Quality Data Collection for Diabetes Research

Business Wire

WEST LAFAYETTE, Ind. -- May 2, 2013

BASi (Bioanalytical Systems, Inc.) (NASDAQ: BASI) announced today that it is
collaborating with Pinnacle Technology Inc. in proof-of-concept studies
combining BASi's Culex® NxT automated blood sampling system with Pinnacle's
glucose sensor to create an innovative new option for high quality data
collection for diabetes and other glucose research.

"The development of new treatments for diabetes is the focus of intense effort
by pharmaceutical companies around the world. Most studies rely on external
monitors to measure glucose levels in test subjects. As a result, researchers
must handle the subjects to obtain blood samples, which causes stress that can
alter glucose readings.

"Our approach has two important advantages over this traditional method:
automation of blood sampling made possible by our Culex NxT, and accurate
monitoring of glucose levels using the Pinnacle glucose sensor with no net
removal of blood from the test subjects. This allows researchers to take many
glucose readings with no ill effects on the test subjects, resulting in more
accurate glucose readings than are possible with manual sampling.

"In addition, the system enables researchers to conduct pharmacokinetic,
metabolism, telemetry or microdialysis studies from one set of test subjects
instead of using three or four sets, thus lowering study costs.

"Pinnacle Technology's glucose sensor was initially built to monitor
neurological glucose levels and adapted to work within the Culex system.
BASi's engineering team developed a new tubing set with a built-in sensor
interface for the Culex NxT, allowing the placement of the sensor into the
blood stream without any stress to the test subjects. Many leading diabetes
research teams have shown great interest in our glucose monitoring system, and
we will work with them to publish the data we are gathering in our
proof-of-concept studies," said Jacqueline M. Lemke, President & CEO and CFO
of BASi.

For further information, please contact Brad Gien, BASi Discovery Services
Scientist PK/PD at 765-497-8491.

About Pinnacle Technology

Pinnacle Technology Inc., based in Lawrence, Kansas, specializes in
researching, designing, and manufacturing turn-key solutions for pre-clinical
Central Nervous System data acquisition and analysis. By forging collaborative
relationships with clients, Pinnacle is able to develop sophisticated new
tools that improve and simplify research. Visit www.pinnaclet.com for more
about Pinnacle Technology.

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research
services and monitoring instruments to the world's leading drug development
companies and medical research organizations. The company focuses on
developing innovative services and products that increase efficiency and
reduce the cost of taking a new drug to market. Visit www.BASinc.com for more
about BASi.

This release contains forward-looking statements that are subject to risks and
 uncertainties including, but not limited to, risks and uncertainties related
    to changes in the market and demand for our products and services, the
    development, marketing and sales of products and services, changes in
 technology, industry standards and regulatory standards, and various market
and operating risks detailed in the company's filings with the Securities and
                             Exchange Commission.

Contact:

BASi (Bioanalytical Systems, Inc.)
Jacqueline Lemke, 765-497-5829
President, CEO and CFO
jlemke@BASinc.com
or
Agency Contact:
Berkman Associates
Neil Berkman, 310-477-3118
info@berkmanassociates.com
 
Press spacebar to pause and continue. Press esc to stop.